Summary
The antihypertensive effects of the regular immediate release formulation of verapamil (verapamil IR) and the newer sustained release formulation of verapamil (verapamil SR) were compared in Hispanic patients with untreated essential hypertension. Verapamil IR was given in 3 divided doses (80 or 160mg 3 times daily) and verapamil SR was given either as a single daily dose of 240mg or as 240mg every 12 hours. With both formulations there was a significant reduction in systolic (SBP) and diastolic blood pressure (DBP); a greater lowering of BP was observed with verapamil 480 mg/day than with 240 mg/day. With verapamil SR 480 mg/day, 91% of patients had reductions in SBP and DBP greater than 20 and 15mm Hg, respectively. In addition, 83% of patients reached normotension. With the lower dose (240mg once daily), 83% of patients had decreases in DBP greater than 10mm Hg and 73% of patients achieved normotension. Comparable effects were achieved with verapamil IR. With verapamil IR there was a more rapid fall in BP which peaked 3 to 4 hours postdose, whereas with verapamil SR a more gradual and sustained BP reduction was observed. Only small changes in heart rate (HR) were observed with verapamil IR and verapamil SR. For verapamil SR, the mean increase in HR was 5 beats/min (to 80 beats/min) and the mean decrease in HR was 13 beats/min (to 62 beats/min). Both verapamil SR and verapamil IR prolonged the PR interval of the ECG. An equal degree of PR prolongation was observed with 240 and 480 mg/day. The incidence of side effects (headache, palpitations, dizziness and flushing) was dose dependent, decreased with continuous treatment and was much higher with verapamil IR than with verapamil SR.
Steady-state plasma verapamil concentrations were monitored. Compared with verapamil IR, verapamil SR produced a more gradual rise and a more sustained elevation of plasma verapamil and norverapamil concentrations. Comparable trough verapamil concentrations (Cmin) were observed with verapamil IR (98 μg/L) and SR (81 μg/L); morning Cmin verapamil concentrations were higher than daytime Cmin values. The normalised area under the plasma concentration-time curve (AUC) and maximum concentration (Cmax) were 10 to 20% greater for verapamil IR than SR. The 2-fold increase in oral dose produced a 2.2- and 2.4-fold increase in AUC for verapamil IR and SR, respectively, associated with a 20% reduction in metabolism to norverapamil.
Fasting increased the rate and extent of absorption of verapamil. This effect was manifested by increases in peak: trough ratios, higher Cmax values, greater AUCs and shorter time to maximum concentration. Fasting increased norverapamil concentrations but did not modify verapamil: norverapamil ratios. In summary, verapamil SR may be substituted for verapamil IR on a milligram to milligram basis. The single or twice-daily administration of verapamil SR simplifies treatment and reduces side effects. Hispanic patients with hypertension had an excellent BP response to treatment with verapamil.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Albernethy DR, Schwartz JB, Todd EL, Luchi R, Snow E. Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients. Annals of Internal Medicine 105: 329–336, 1986
Anavekar SN, Barter C, Adam WR, Doyle AE. A double-blind comparison of verapamil and labetalol in hypertensive patients with coexisting chronic obstructive airways disease. Journal of Cardiovascular Pharmacology 4: S374–S377, 1982
Brugmann U. Calcium antagonists in hypertension and coronary heart disease: results from a double-blind, randomized, placebo-controlled study with verapamil SR 240 mg. In Fleckenstein A, Laragh JH (Eds) Hypertension–the next decade: verapamil in focus, pp. 106–113, Churchill Livingstone, Edinburgh, 1987
Cubeddu LX, Aranda J, Sing B, Klein M, Brachfeld J, et al. A comparison of verapamil and propranolol for the initial treatment of hypertension: racial differences in response. Journal of the American Medical Association 256: 2214–2221, 1986
Cubeddu LX. Racial differences in response to antihypertensive drugs: a focus on verapamil. Journal of Clinical Hypertension 3: 72S–78S, 1986
de Faire U, Forslund L, Andersson P, Bondesson V, Hedbacl B, et al. The antihypertensive effect of verapamil in twice and thrice daily dose regimens. Subanalysis of 24 h blood pressure profiles. In Fleckenstein A, Laragh JH (Eds) Hypertension–the next decade: verapamil in focus, pp. 351–353, Churchill Livingstone, Edinburgh, 1987
Halperin AG, Gross KM, Rogers JF, Cubeddu LX. Verapamil and propranolol in essential hypertension. Clinical Pharmacology and Therapeutics 36: 750–758, 1984
Halperin A, Cubeddu LX. Role of calcium channel blockers in the treatment of hypertension. American Heart Journal 111: 328–363, 1986
Harapat S, Kates R. High performance liquid Chromatographic analysis of verapamil. II. Simultaneous quantitation of verapamil and its active metabolite, norverapamil. Journal of Chromatography 181: 484–489, 1980
Katz AM. Pharmacology and mechanisms of action of calcium channel blockers. Journal of Clinical Hypertension 2: 28S–37S, 1986
Kingma JH, Bernink PJLM, van Gilst WH, Kerkkamp HJJ, Wesseling H. Comparison of instant and slow release verapamil in patients with hypertension and coronary artery disease. In Fleckenstein A, Laragh JH (Eds) Hypertension–the next decade: verapamil in focus, pp. 250–253, Churchill Livingstone, Edinburgh, 1987
Kirsten EB, Guerrero J, Müller-Peltzer. Pharmacokinetics of verapamil slow release formulation. In Fleckenstein A, Laragh JH (Eds) Hypertension–the next decade: verapamil in focus, pp. 274–279, Churchill Livingstone, Edinburgh, 1987
Koike Y, Shimamura K, Shudo I, Saito H. Pharmacokinetics of verapamil in man. Research Communications in Chemistry, Pathology and Pharmacology 24: 37–47, 1979
McAllister RG. Clinical pharmacokinetics of calcium channel antagonists. Journal of Cardiovascular Pharmacology 4: 340S–345S, 1982
McAllister RG, Schloemer GI, Hamann SR. Kinetics and dynamics of calcium entry antagonists in systemic hypertension. American Journal of Cardiology 26: 16D–21D, 1986
Midtbo KA, Hals O, Lauve O. A new sustained-release formulation of verapamil in the treatment of hypertension. Journal of Clinical Hypertension 3: 125S–132S, 1986
Schomerus M, Spiegelhalder B, Stieren B, Eichelbaum M. Physiologic disposition of verapamil in man. Cardiovascular Research 10: 605–612, 1976
Singh BN, Nademanee K. Use of calcium antagonists for cardiac arrhythmias. American Journal of Cardiology 59: 153B–162B, 1987
Veterans Administration Cooperative Study Group on Antihypertensive Agents. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. I. Results of short term titration with emphasis on racial differences in responses. Journal of the American Medical Association 248: 22–29, 1982a
Veterans Administration Cooperative Study Group on Antihypertensive Agents. Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide. British Journal of Pharmacology 14: 975–1015, 1982b
Weiner DA, Klein MD, Cutler SS. Efficacy of sustained-release verapamil in chronic stable angina pectoris. American Journal of Cardiology 59: 215–218, 1987
Zachariah PK, Sheps SG, Schirger A, Spiekerman RE, Simpson KK. Verapamil and 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. American Journal of Cardiology 57: 74D–79D, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fuenmayor, N.T., Faggin, B.M. & Cubeddu, L.X. Comparative Efficacy, Safety and Pharmacokinetics of Verapamil SR vs Verapamil IR in Hypertensive Patients. Drugs 44 (Suppl 1), 1–11 (1992). https://doi.org/10.2165/00003495-199200441-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199200441-00002